Introducing a novel therapy for type 2 diabetes to primary care

Postgrad Med. 2020 Nov;132(sup2):1-2. doi: 10.1080/00325481.2020.1798686. Epub 2020 Sep 8.

Author

Stephen A Brunton¹

Affiliation

¹ Touro University California , Vallejo, CA, USA.

PMID: 32897147
DOI: 10.1080/00325481.2020.1798686

No abstract available

Keywords: Type 2 diabetes; glucagon-like peptide-1 receptor agonist; oral semaglutide; primary care.

MeSH terms

Blood Pressure
Diabetes Mellitus, Type 2 / drug therapy*
Diabetes Mellitus, Type 2 / therapy
Glucagon-Like Peptide-1 Receptor / agonists
Glycated Hemoglobin
Humans
Hypoglycemic Agents / administration & dosage
Hypoglycemic Agents / adverse effects
Hypoglycemic Agents / therapeutic use*
Lipids / blood
Practice Guidelines as Topic
Primary Health Care / organization & administration*
Primary Health Care / standards

Substances

Glucagon-Like Peptide-1 Receptor
Glycated Hemoglobin A
Hypoglycemic Agents
Lipids